LANXESS IS NO GERMAN ARKEMA QUITE YET (REDUCE; +8% UPSIDE)
01/10/24 -" Lanxess’ (Reduce; Germany) equity story is a difficult one. At first sight, the company seems to have the portfolio rotation gene, but there is hardly any positive effect to be identified. Lanxess ..."
Pages
59
Language
English
Published on
01/10/24
You may also be interested by these reports :
03/11/26
Clariant’s Q3 2026 growth was price-led, though underlying volumes improved in Care Chemicals and A&A. Middle East conflict weighed on Catalysts. ...
02/11/26
Fuchs reported a strong but price-led Q3 2026, a shift from volume-led Q2 2026. EBIT recorded its all-time high as supply constraints pushed prices. ...
30/10/26
Following preliminary Q3 results announced earlier, Fuchs confirmed strong sales and EBIT growth of 25% and 27%, respectively. However, organic ...
29/10/26
Wacker’s Q3 2026 sales growth was price-led, reflecting cost pass-through rather than a recovery in demand. The chemicals divisions led earnings, ...